🔎 Trials Near Me

Akèy › Leksemi biphenotipik egi › Washington › Seattle

Etid klinik pou Leksemi biphenotipik egi nan Seattle, WA

15 etid pou Leksemi biphenotipik egi ap chèche patisipan nan sit nan ak bò kote Seattle (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Ap rekriteFaz 1
  • Fred Hutchinson Cancer Center, Seattle
Laj 12 a 78 · Tout sèks · Mizajou Sep 29, 2026 · NCT03802695

Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms

Ap rekrite
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07094750

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Ap rekriteFaz 3
  • Seattle Children's Hospital, Seattle
365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Ap rekriteFaz 2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
6 Months – 65 Years · Tout sèks · Mizajou Jul 22, 2026 · NCT06013423

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Ap rekriteFaz 1/2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Laj 18 a 75 · Tout sèks · Mizajou Jun 22, 2026 · NCT03128034

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Ap rekriteFaz 1/2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Laj 18 a 75 · Tout sèks · Mizajou Jun 22, 2026 · NCT03670966

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Ap rekriteFaz 2Volontè an sante akeyi
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
6 Months · Tout sèks · Mizajou May 29, 2026 · NCT04195633

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Ap rekriteFaz 1
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Jiska laj 80 · Tout sèks · Mizajou May 18, 2026 · NCT03326921

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Ap rekriteFaz 1/2Volontè an sante akeyi
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Laj 18 ak plis · Tout sèks · Mizajou May 15, 2026 · NCT06928662

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Ap rekriteFaz 1/2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Apr 17, 2026 · NCT04797767

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Ap rekriteFaz 1
  • Seattle Children's Hospital, Seattle
Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770

Etid Leksemi biphenotipik egi nan lòt vil

Lòt etid nan Seattle

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.